Search :
Sign in or Register  
Welcome Sign in or Don't have an account?Register

Mouse Anti-CDKN2A Recombinant Antibody (CBYY-C1806) (CBMAB-C3244-YY)


See all CDKN2A antibodies
Online Inquiry
Published Data
CBMAB-C3244-YY-1
Mouse Anti-CDKN2A Recombinant Antibody (CBYY-C1806) (CBMAB-C3244-YY) in WB
PTEN and p16INK4A protein analysis by Western blot. NIH3T3 is a mouse fibroblast cell line used as a positive control for PTEN expression study. Human OSA cell line SAOS2 is used as a positive control for p16INK4A. The number under each cell line designation indicates the PTEN protein band intensity normalized to β-actin and compared to NIH3T3. ...View More
Yang, Y. T., Engleberg, A. I., & Yuzbasiyan-Gurkan, V. (2023). Establishment and Characterization of Cell Lines from Canine Metastatic Osteosarcoma. Cells, 13(1), 25.
Distributed under Open Access license CC BY 4.0, without modification.
CBMAB-C3244-YY-2
Mouse Anti-CDKN2A Recombinant Antibody (CBYY-C1806) (CBMAB-C3244-YY) in WB
The expression analysis of the p16 protein in canine lymphoma cell lines. The protein expression was assessed using western blot analysis. ...View More
Maylina, L., Kambayashi, S., Baba, K., & Okuda, M. (2022). Simultaneous analysis of the p16 gene and protein in canine lymphoma cells and their correlation with pRb phosphorylation. Veterinary Sciences, 9(8), 393.
Distributed under Open Access license CC BY 4.0, without modification.
CBMAB-C3244-YY-3
Mouse Anti-CDKN2A Recombinant Antibody (CBYY-C1806) (CBMAB-C3244-YY) in WB
P16 antibody (F-8) binds human and canine P16 protein in a immunoblot assay. An appropriate size band (~15-16 kDa) is present in protein lysates derived from cells or tissues known to express P16 (lane 1- human osteosarcoma SAOS2; lane 2-high grade canine oligodendroglioma 08; lane 3- canine GBM G2). ...View More
Murphy, B. G., Mok, M. Y., York, D., Rebhun, R., Woolard, K. D., Hillman, C., ... & Skorupski, K. (2017). Evaluation of P16 expression in canine appendicular osteosarcoma. BMC veterinary research, 13, 1-9.
Distributed under Open Access license CC BY 4.0, without modification.
CBMAB-C3244-YY-4
Mouse Anti-CDKN2A Recombinant Antibody (CBYY-C1806) (CBMAB-C3244-YY) in IHC
Immunohistochemistry assays reveal the proportion of neoplastic cells expressing P16. Canine glioblastoma cells demonstrate abundant red-brown staining in both the cytoplasm and nucleus (GBM, + control P16 IHC) (a). Normal canine brain tissue demonstrates an absence of red-brown stained cells (NB, negative control P16 IHC) (b). In a canine OSA, a majority of the neoplastic cells demonstrate red-brown cytoplasmic staining (3+ staining, case 19) (c). In a canine OSA, approximately 50% of the neoplastic cells demonstrate red-brown cytoplasmic staining (2+ staining, case 9) (d). In canine OSA, less than 25% of the neoplastic cells demonstrate red-brown cytoplasmic staining (1+ staining, case 4) (e). In canine OSA, none of the neoplastic cells demonstrate red-brown cytoplasmic staining (0+ staining, case 13). P16 immunohistochemistry, original magnification 400×. ...View More
Murphy, B. G., Mok, M. Y., York, D., Rebhun, R., Woolard, K. D., Hillman, C., ... & Skorupski, K. (2017). Evaluation of P16 expression in canine appendicular osteosarcoma. BMC veterinary research, 13, 1-9.
Distributed under Open Access license CC BY 4.0, without modification.

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBYY-C1806
Antibody Isotype
IgG2a
Application
WB, IP, IF, ELISA

Basic Information

Immunogen
Amino acids 4-31 at the N-terminus of p16 INK4A of human.
Host Species
Mouse
Specificity
Human
Antibody Isotype
IgG2a
Clonality
Monoclonal Antibody
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.
ApplicationNote
WB1:100-1:1,000
IP1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)
IF(ICC)1:50-1:500
ELISA1:100-1:1,000

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
PBS, 0.1% gelatin
Preservative
< 0.1% sodium azide
Concentration
0.2 mg/ml
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Cyclin Dependent Kinase Inhibitor 2A
Entrez Gene ID
1029
UniProt ID
P42771
Alternative Names
Caudal Type Homeobox 2; Caudal-Type Homeobox Protein 2; CDX-3; CDX3; Caudal Type Homeo Box Transcription Factor 2; Caudal Type Homeobox Transcription Factor 2; Homeobox Protein MiniCDX2; Homeobox Protein CDX-2; CDX2/AS;
Function
Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.
Biological Process
Cell cycle arrest Source: BHF-UCL
Cellular senescence Source: BHF-UCL
G1/S transition of mitotic cell cycle Source: BHF-UCL
Negative regulation of cell growth Source: BHF-UCL
Negative regulation of cell-matrix adhesion Source: BHF-UCL
Negative regulation of cell population proliferation Source: BHF-UCL
Negative regulation of cyclin-dependent protein serine/threonine kinase activity Source: BHF-UCL
Negative regulation of G1/S transition of mitotic cell cycle Source: Reactome
Negative regulation of NF-kappaB transcription factor activity Source: BHF-UCL
Negative regulation of phosphorylation Source: BHF-UCL
Negative regulation of transcription, DNA-templated Source: UniProtKB
Positive regulation of cellular senescence Source: UniProtKB
Positive regulation of macrophage apoptotic process Source: BHF-UCL
Positive regulation of smooth muscle cell apoptotic process Source: BHF-UCL
Ras protein signal transduction Source: BHF-UCL
Regulation of transcription initiation from RNA polymerase II promoter Source: Reactome
Replicative senescence Source: BHF-UCL
Senescence-associated heterochromatin focus assembly Source: UniProtKB
Cellular Location
Nucleus; Cytoplasm
Involvement in disease
The association between cutaneous and uveal melanomas in some families suggests that mutations in CDKN2A may account for a proportion of uveal melanomas. However, CDKN2A mutations are rarely found in uveal melanoma patients.
Melanoma, cutaneous malignant 2 (CMM2): A malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites.
Familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC): An inherited cancer predisposition syndrome characterized by an increased risk of developing malignant melanoma and/or pancreatic cancer. Mutation carriers within families may develop either or both types of cancer.
Melanoma-astrocytoma syndrome (MASTS): Characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma.
PTM
Phosphorylation seems to increase interaction with CDK4.
More Infomation

Xu, J., Li, N., Deng, W., & Luo, S. (2021). Discovering the mechanism and involvement of the methylation of cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and its special locus region in gastric cancer. Bioengineered, 12(1), 1286-1298.

Salmani, T., Ghaderian, S. M. H., Hajiesmaeili, M., Mirghaed, O. R., Rakhshan, A., Nasiri, M. J., & Mohammadi, M. (2020). Cyclin dependent kinase inhibitor 2A and miR-671-5p expression profile in Iranian glioblastoma multiforme. Gene Reports, 19, 100620.

Althakfi, W., Gazzo, S., Blanchet, M., Isaac, S., Piaton, E., Villeneuve, L., ... & Brevet, M. (2020). The value of BRCA‐1‐associated protein 1 expression and cyclin‐dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens. Cytopathology, 31(1), 5-11.

Seifi, S., Pouya, F., Rahmani, M., Mehramiz, M., Rastgar‐Moghadam, A., Gharib, M., ... & Avan, A. (2020). Association of cyclin‐dependent kinase inhibitor 2A/B with increased risk of developing breast cancer. Journal of cellular physiology, 235(6), 5141-5145.

Zhang, H. H., Mao, J. S., & Hu, W. F. (2019). Functional genetic single-nucleotide polymorphisms (SNPs) in cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) locus are associated with risk and prognosis of osteosarcoma in chinese populations. Medical science monitor: international medical journal of experimental and clinical research, 25, 1307.

Zhang, W., Kuang, P., & Liu, T. (2019). Prognostic significance of CDKN2A/B deletions in acute lymphoblastic leukaemia: a meta-analysis. Annals of medicine, 51(1), 28-40.

Agarwal, M., Bakhshi, S., Dwivedi, S. N., Kabra, M., Shukla, R., & Seth, R. (2018). Cyclin dependent kinase inhibitor 2A/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia. Pediatric blood & cancer, 65(6), e27001.

O'Hara, S. P., Splinter, P. L., Trussoni, C. E., Pisarello, M. J. L., Loarca, L., Splinter, N. S., ... & LaRusso, N. F. (2017). ETS proto-oncogene 1 transcriptionally up-regulates the cholangiocyte senescence-associated protein cyclin-dependent kinase inhibitor 2A. Journal of Biological Chemistry, 292(12), 4833-4846.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-CDKN2A Recombinant Antibody (CBYY-C1806)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Learn more

Documents

Request bulk or custom quoteOnline Inquiry
Second antibody and isotype control

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Online Inquiry